Singapore markets open in 2 hours 50 minutes

Kura Oncology, Inc. (KURA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
20.63+0.04 (+0.19%)
At close: 04:00PM EDT
20.63 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close20.59
Open20.55
Bid20.59 x 400
Ask20.66 x 200
Day's range20.26 - 21.25
52-week range7.41 - 24.17
Volume605,625
Avg. volume920,808
Market cap1.572B
Beta (5Y monthly)0.87
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 67,950 shares of common stock to six (6) new employees under the

  • GlobeNewswire

    Kura Oncology Reports First Quarter 2024 Financial Results

    – Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data for ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – First patient dosed with KO-2806 and cabozantinib in renal cell carcinoma – – $527 million in cash, cash equivalents and investments provide runway into 2027 – – Management to host webcast and conference call today at 4:3

  • GlobeNewswire

    Kura Oncology to Report First Quarter 2024 Financial Results

    SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2024 financial results after the close of U.S. financial markets on Thursday, May 2, 2024. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a co